BR112016028816A2 - combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório, e, kit. - Google Patents

combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório, e, kit.

Info

Publication number
BR112016028816A2
BR112016028816A2 BR112016028816A BR112016028816A BR112016028816A2 BR 112016028816 A2 BR112016028816 A2 BR 112016028816A2 BR 112016028816 A BR112016028816 A BR 112016028816A BR 112016028816 A BR112016028816 A BR 112016028816A BR 112016028816 A2 BR112016028816 A2 BR 112016028816A2
Authority
BR
Brazil
Prior art keywords
immunogenic
immunogenic combination
immune response
specific immune
syncytial virus
Prior art date
Application number
BR112016028816A
Other languages
English (en)
Other versions
BR112016028816A8 (pt
Inventor
Vitelli Alessandra
Steff Ann-Muriel
Toussaint Jean-Francois
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BR112016028816A2 publication Critical patent/BR112016028816A2/pt
Publication of BR112016028816A8 publication Critical patent/BR112016028816A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

essa descrição se refere a combinações imunogênicas que incluem a) um componente imunogênico que contém um antígeno de peptídeo ou polipeptídeo de um patógeno respiratório; e b) um componente imunogênico que contém um ácido nucleico que codifica um antígeno do mesmo patógeno respiratório, em que os componentes imunogênicos são formulados para administração concomitante, por exemplo, colocalizada. mais especificamente, o patógeno respiratório é o vírus sincicial respiratório (rsv). essa descrição também se refere a fornecer o uso de tais combinações imunogênicas, e métodos para administrar tais combinações imunogênicas para obter uma resposta imunológica específica para o patógeno respiratório
BR112016028816A 2014-06-13 2015-06-12 combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, e, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório BR112016028816A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462011712P 2014-06-13 2014-06-13
PCT/EP2015/063248 WO2015189425A1 (en) 2014-06-13 2015-06-12 Immunogenic combinations

Publications (2)

Publication Number Publication Date
BR112016028816A2 true BR112016028816A2 (pt) 2017-08-22
BR112016028816A8 BR112016028816A8 (pt) 2021-07-20

Family

ID=53498962

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016028816A BR112016028816A8 (pt) 2014-06-13 2015-06-12 combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, e, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório

Country Status (8)

Country Link
US (2) US11571472B2 (pt)
EP (2) EP3154576A1 (pt)
JP (1) JP6664338B2 (pt)
CN (1) CN106659777A (pt)
BR (1) BR112016028816A8 (pt)
CA (1) CA2951430A1 (pt)
MX (1) MX2016016533A (pt)
WO (1) WO2015189425A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107810009A (zh) 2015-05-15 2018-03-16 库瑞瓦格股份公司 涉及施用至少一种mRNA构建体的初免‑加强方案
US11254711B2 (en) 2015-06-12 2022-02-22 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
ES2937963T3 (es) 2015-07-21 2023-04-03 Modernatx Inc Vacunas de enfermedad infecciosa
EP3364982A4 (en) 2015-10-22 2019-04-17 ModernaTX, Inc. VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES
EA201891001A1 (ru) 2015-10-22 2018-11-30 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv)
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
PE20190433A1 (es) 2016-04-05 2019-03-21 Janssen Vaccines And Prevention B V Vacuna contra vrs
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
EP3538146A4 (en) 2016-11-11 2020-07-15 ModernaTX, Inc. INFLUENZA VACCINE
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
EP3551644B1 (en) * 2016-12-09 2023-08-16 GlaxoSmithKline Biologicals SA Chimpanzee adenovirus constructs with lyssavirus antigens
GB201701239D0 (en) * 2017-01-25 2017-03-08 Glaxosmithkline Biologicals Sa Novel formulation
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS VACCINE
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
MA52262A (fr) 2017-03-15 2020-02-19 Modernatx Inc Vaccin à large spectre contre le virus de la grippe
MA50253A (fr) 2017-09-14 2020-07-22 Modernatx Inc Vaccins à arn contre le virus zika
WO2019055768A1 (en) * 2017-09-15 2019-03-21 Ohio State Innovation Foundation VACCINES AND METHODS OF MAKING AND USING VACCINES FOR THE PREVENTION OF SYNCYTIAL RESPIRATORY VIRUS (RSV) INFECTIONS
JP2021500880A (ja) * 2017-10-16 2021-01-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ２つの発現カセットを有するサルアデノウイルスベクター
BR112020007008A2 (pt) * 2017-10-16 2020-11-17 Glaxosmithkline Biologicals S.A. vetores adenovirais com dois cassetes de expressão codificando proteínas antigênicas do rsv ou fragmentos das mesmas
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
CN111801342A (zh) 2017-12-20 2020-10-20 葛兰素史密丝克莱恩生物有限公司 爱泼斯坦-巴尔病毒抗原构建体
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
US11517618B2 (en) 2018-09-25 2022-12-06 Janssen Vaccines & Prevention B.V. Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US20230233661A1 (en) * 2020-06-29 2023-07-27 Janssen Vaccines & Prevention B.V. Vaccine combination against repiratory syncytial virus infection
WO2023183136A1 (en) * 2022-03-11 2023-09-28 National Health Research Institutes Composition comprising antigen and dna and use thereof
WO2023217189A2 (zh) * 2022-05-10 2023-11-16 康希诺生物股份公司 一种呼吸道合胞病毒腺病毒载体疫苗及其制备方法和应用

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5520A (en) 1848-04-18 Oegan-pipb
US639A (en) 1838-03-17 of boston
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4707543A (en) 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5726292A (en) 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6511845B1 (en) 1992-08-07 2003-01-28 Alan R. Davis Methods for producing an immune response against HIV-1
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
CN1087176C (zh) 1993-03-23 2002-07-10 史密斯克莱·比奇曼生物公司 含有3－o脱酰基单磷酰脂a的疫苗制剂
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1995014026A1 (en) 1993-11-17 1995-05-26 Laboratoires Om S.A. Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
ES2267100T5 (es) 1994-07-15 2011-04-08 The University Of Iowa Research Foundation Oligonucleótidos inmunomoduladores.
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US6180398B1 (en) 1996-07-12 2001-01-30 Virogeneitics Corporation Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
SK18602000A3 (sk) 1998-06-08 2001-07-10 Sca Emballage France Obal umožňujúci rýchle vyrovnanie
HUP0102475A3 (en) 1998-06-30 2001-12-28 Om Pharma Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6379324B1 (en) 1999-06-09 2002-04-30 The Procter & Gamble Company Intracutaneous microneedle array apparatus
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
NZ524661A (en) 2000-11-23 2005-03-24 Bavarian Nordic As Modified vaccinia ankara virus variant
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
WO2002072012A2 (en) 2001-03-09 2002-09-19 Id Biomedical Corporation Of Quebec A novel proteosome-liposaccharide vaccine adjuvant
JP4331944B2 (ja) 2001-04-17 2009-09-16 大日本住友製薬株式会社 新規アデニン誘導体
PT1409012E (pt) 2001-06-22 2009-05-11 Wistar Inst Métodos de indução de uma resposta imunitária citotóxica e composições de adenovírus recombinantes de símio úteis para esse efeito
US20040087992A1 (en) 2002-08-09 2004-05-06 Vladimir Gartstein Microstructures for delivering a composition cutaneously to skin using rotatable structures
JP2005513021A (ja) 2001-11-16 2005-05-12 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトール様受容体経路に関する方法および組成物
JP2006517974A (ja) 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
NZ548107A (en) 2003-12-24 2009-09-25 Nederlanden Staat A respiratory syncytial virus with a genomic deficiency complemented in trans
CN107723298A (zh) 2004-01-23 2018-02-23 Msd意大利有限公司 黑猩猩腺病毒疫苗载运体
CA2567446C (en) 2004-05-21 2018-01-02 Chiron Corporation Alphavirus vectors for respiratory pathogen vaccines
AU2005306372B2 (en) 2004-11-18 2011-01-06 Kindeva Drug Delivery L.P. Method of contact coating a microneedle array
CN101102809B (zh) 2004-11-18 2010-05-26 3M创新有限公司 涂敷微针阵列的遮蔽方法
EP2001516A4 (en) 2006-03-10 2010-04-28 Univ California VACCINATES AGAINST PERSISTENT OR LATENT INFECTIONS THREADING VIRUSES
WO2008133663A2 (en) 2006-11-30 2008-11-06 Government Of The United States Of America, As Represented By The Secretary, Codon modified immunogenic compositions and methods of use
WO2008085502A2 (en) 2007-01-05 2008-07-17 Inseron, Inc. A green fluorescent protein optimized for expression with self-cleaving polypeptides
BRPI0808553A2 (pt) 2007-03-02 2014-08-19 Glaxosmithkline Biolog Sa Métodos para elevar uma resposta imune contra um patógeno, para estimar a produção de células t cd4+ e/ou cd8+ e/ou anticorpos específicos de patógeno em mamíferos e para estimular uma resposta imune em um mamífero, composição de vacina, uso da mesma, e, kit
CA2684578A1 (en) 2007-03-21 2008-09-25 Id Biomedical Corporation Of Quebec Chimeric antigens
GB0706914D0 (en) 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
CA2686093C (en) 2007-04-16 2018-05-08 Corium International, Inc. Solvent-cast microneedle arrays containing active
US20090092635A1 (en) 2007-08-17 2009-04-09 Wyeth Heterologous prime-boost immunization regimen
CL2007002710A1 (es) 2007-09-20 2008-01-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.
US7863425B2 (en) 2007-09-26 2011-01-04 Cornell University Compositions and methods for inhibiting Yersinia pestis infection
WO2009048607A1 (en) 2007-10-10 2009-04-16 Corium International, Inc. Vaccine delivery via microneedle arrays
EA021393B1 (ru) 2007-12-24 2015-06-30 Глаксосмитклайн Байолоджикалс С.А. Рекомбинантные антигены rsv
WO2010009277A2 (en) 2008-07-15 2010-01-21 Novartis Ag Immunogenic amphipathic peptide compositions
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
KR101763093B1 (ko) 2009-02-02 2017-07-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도
US20110006458A1 (en) 2009-04-24 2011-01-13 Corium International, Inc. Methods for manufacturing microprojection arrays
CN102740880A (zh) 2009-05-18 2012-10-17 万能药生物有限公司 基于重组修饰的安卡拉痘苗（mva）病毒的通用流感疫苗
SI2445526T1 (sl) 2009-06-24 2016-08-31 Glaxosmithkline Biologicals S.A. Rekombinantni RSV antigeni
WO2011005799A2 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
ES2918381T3 (es) 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa Composiciones de proteína F de VRS y métodos para producir las mismas
US9095546B2 (en) 2009-07-20 2015-08-04 National Health Research Institutes Human respiratory syncytial virus (RSV) vaccine
EP2590670B1 (en) 2010-07-06 2017-08-23 GlaxoSmithKline Biologicals SA Methods of raising an immune response by delivery of rna
WO2012006376A2 (en) 2010-07-06 2012-01-12 Novartis Ag Virion-like delivery particles for self-replicating rna molecules
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
US9173933B2 (en) 2010-10-15 2015-11-03 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara influenza vaccine
WO2012085936A2 (en) 2010-12-20 2012-06-28 Panacea Biotech Ltd Recombinant respiratory syncytial virus plasmids and vaccines
WO2012089231A1 (en) 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
KR20220047790A (ko) 2011-03-21 2022-04-19 알티뮨 인크. 급속 및 지속적 면역학적제제-치료제
PT2707385T (pt) 2011-05-13 2017-12-19 Glaxosmithkline Biologicals Sa Antigénios de f de rsv pré-fusão
EP2729165B1 (en) 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
JP2014520807A (ja) 2011-07-06 2014-08-25 ノバルティス アーゲー 免疫原性組成物およびその使用
CN103239734B (zh) 2012-02-10 2016-02-24 北京艾棣维欣生物技术有限公司 用于预防和/或治疗呼吸道合胞病毒感染的疫苗
CN104334188B (zh) * 2012-03-22 2016-08-24 克鲁塞尔荷兰公司 抗rsv疫苗
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
WO2014005643A1 (en) * 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
CA2879915C (en) 2012-08-01 2022-07-05 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
CN104853769A (zh) * 2012-11-20 2015-08-19 葛兰素史密丝克莱恩生物有限公司 Rsv f融合前三聚体
US20140141037A1 (en) 2012-11-20 2014-05-22 Novartis Ag Rsv f prefusion trimers

Also Published As

Publication number Publication date
CA2951430A1 (en) 2015-12-17
EP3888676A1 (en) 2021-10-06
WO2015189425A1 (en) 2015-12-17
JP2017523139A (ja) 2017-08-17
CN106659777A8 (zh) 2017-07-07
BR112016028816A8 (pt) 2021-07-20
EP3154576A1 (en) 2017-04-19
JP6664338B2 (ja) 2020-03-13
MX2016016533A (es) 2017-05-01
US11571472B2 (en) 2023-02-07
US20230390381A1 (en) 2023-12-07
US20170143820A1 (en) 2017-05-25
CN106659777A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
BR112016028816A2 (pt) combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório, e, kit.
EA201890731A1 (ru) Модуляторы корового белка гепатита b
BR112018068748A2 (pt) composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto
MX2018005569A (es) Vacunas contra el virus de la hepatitis b.
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
MX2019003525A (es) Moduladores alostericos de proteina nucleo de hepatitis b.
MX2021007679A (es) Anticuerpos humanos para hemaglutinina de influenza.
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
BR112016028066A2 (pt) composição de vacina; idessuis; ridessuis; anticorpo; composição parenteral; uso de uma proteína idessuis ou ridessuis; e célula hospedeira
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
EA201391515A1 (ru) Инактивированная вакцина вируса денге
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
BR112013000345A2 (pt) composições antigênicas para vírus sincicial respiratório e métodos
CO2020005485A2 (es) Administración oral de análogos del péptido glp-1
MX2019007924A (es) Vacunas contra la influenza.
PH12017501943A1 (en) Influenza virus neutralizing peptidomimetic compounds
BR112017012546A2 (pt) composição de vacina antirrábica, kit farmacêutico e uso da composição de vacina antirrábica
EA201892095A1 (ru) Циклические динуклеотидные соединения и способы их применения
EA201600316A2 (ru) ПРОТИВОТУБЕРКУЛЕЗНАЯ ВАКЦИНА НА ОСНОВЕ РЕКОМБИНАНТНЫХ БЕЛКОВ Ag85B, TB10.4, FLiC
PL408955A1 (pl) Immunogenny koniugat i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez pałeczki jelitowe z rodziny Enterobacteriaceae
EA201691202A1 (ru) Флагеллин-содержащие белковые наночастицы в качестве платформы для вакцины
IL240241B (en) Antibodies directed to bacillus anthracis protective antigen
EA201691835A1 (ru) Аллостерические модуляторы капсидного белка гепатита в

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]